Overview

A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers

Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the safety and pharmacokinetics of subcutaneous lebrikizumab in healthy Japanese volunteers. Healthy Japanese and Caucasian volunteers will be randomized to receive a single subcutaneous dose of either lebrikizumab or placebo.
Phase:
Phase 1
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Antibodies, Monoclonal